Clinical characteristics and treatment strategies of 79 patients with COVID-19

Q4 Pharmacology, Toxicology and Pharmaceutics 中国药理学通报 Pub Date : 2020-04-01 DOI:10.3969/J.ISSN.1001-1978.2020.04.002

Xiaowei Fang, Q. Mei, Tian-jun Yang, Lei Zhang, Yun Yang, Yin Wang, Fei Tong, Chongyang Ye, Yu Gao, Yao Huang, Shike Geng, A. Pan

{"title":"Clinical characteristics and treatment strategies of 79 patients with COVID-19","authors":"Xiaowei Fang, Q. Mei, Tian-jun Yang, Lei Zhang, Yun Yang, Yin Wang, Fei Tong, Chongyang Ye, Yu Gao, Yao Huang, Shike Geng, A. Pan","doi":"10.3969/J.ISSN.1001-1978.2020.04.002","DOIUrl":null,"url":null,"abstract":"Aim To analyze the clinical characteristics of patients of corona virus disease 2019 (COVID-19), and summarize the treatment experience, aiming to provide diagnostic and treatment reference for the front-line clinicians Methods Seventy-nine patients with COVID-19 admitted to the Infectious Hospital of Anhui Provincial Hospital from January 22 to February 18, 2020 were selected as the research subjects There were 55 cases in general group and 24 cases in severe and critical group The clinical data of the two groups were collected and compared, including general conditions, clinical symptoms, signs, laboratory tests, computed tomography imaging of the lungs and complications Results The average age of 79 COVID-19 patients was 45 1 ± 16 6 years, and forty-five of them are males The severe and critical group was older than the general group Besides, there were more males and comorbidities In terms of laboratory tests, the lymphocyte (LYM) count and albumin (A L B) decreased more significantly in the severe and critical groups Moreover, the percentage of neutrophils (N E U), c-reactive protein (CRP), D-dimer, lactate dehydrogenase (L D H), troponin I (cTnl) and urea nitrogen (BUN) increased significantly Among all the patients, the types of antiviral drugs in severe and critical group were significantly more than those in general group;moreover, the glucocorticoids, gamma globulin and oxygen inhalation by nasal catheter were used more frequently in severe and critical patients By the time of February 18, one patient died of acute large area cerebral infarction, 34 patients were discharged from hospital, and the rest were still receiving treatment Conclusions The elderly patients with multiple cardiovascular diseases are more likely to get severe and critical COVID-19 They usually combine multiple organ or system abnormalities Clinicians should make timely judgment and adjust the treatment plan according to the clinical symptoms, signs and laboratory examination results","PeriodicalId":10296,"journal":{"name":"中国药理学通报","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"31","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国药理学通报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3969/J.ISSN.1001-1978.2020.04.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 31

Abstract

Aim To analyze the clinical characteristics of patients of corona virus disease 2019 (COVID-19), and summarize the treatment experience, aiming to provide diagnostic and treatment reference for the front-line clinicians Methods Seventy-nine patients with COVID-19 admitted to the Infectious Hospital of Anhui Provincial Hospital from January 22 to February 18, 2020 were selected as the research subjects There were 55 cases in general group and 24 cases in severe and critical group The clinical data of the two groups were collected and compared, including general conditions, clinical symptoms, signs, laboratory tests, computed tomography imaging of the lungs and complications Results The average age of 79 COVID-19 patients was 45 1 ± 16 6 years, and forty-five of them are males The severe and critical group was older than the general group Besides, there were more males and comorbidities In terms of laboratory tests, the lymphocyte (LYM) count and albumin (A L B) decreased more significantly in the severe and critical groups Moreover, the percentage of neutrophils (N E U), c-reactive protein (CRP), D-dimer, lactate dehydrogenase (L D H), troponin I (cTnl) and urea nitrogen (BUN) increased significantly Among all the patients, the types of antiviral drugs in severe and critical group were significantly more than those in general group;moreover, the glucocorticoids, gamma globulin and oxygen inhalation by nasal catheter were used more frequently in severe and critical patients By the time of February 18, one patient died of acute large area cerebral infarction, 34 patients were discharged from hospital, and the rest were still receiving treatment Conclusions The elderly patients with multiple cardiovascular diseases are more likely to get severe and critical COVID-19 They usually combine multiple organ or system abnormalities Clinicians should make timely judgment and adjust the treatment plan according to the clinical symptoms, signs and laboratory examination results

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

79例新冠肺炎患者的临床特点及治疗对策

目的分析2019冠状病毒病(COVID-19)患者的临床特征，总结治疗经验，旨在为一线临床医生提供诊断和治疗参考方法1月22日至2月18日安徽省立医院感染性医院收治的79例COVID-19患者，2020年被选为研究对象一般有55例组,24例严重和重要组两组临床资料的收集和比较,包括一般情况、临床症状、体征、实验室测试、计算机断层扫描成像的肺部和并发症结果79 COVID-19患者的平均年龄是45 1±16 6年,其中45是男性严重和重要组比一般群体之外,在实验室检查方面，重症和危重症组淋巴细胞(LYM)计数和白蛋白(A L B)下降更为明显，中性粒细胞(N E U)、c反应蛋白(CRP)、D-二聚体、乳酸脱氢酶(L D H)、肌钙蛋白I (cTnl)和尿素氮(BUN)百分比均显著升高。重症、危重症患者使用抗病毒药物的种类明显多于普通组，且重症、危重症患者使用糖皮质激素、丙种球蛋白、鼻导管吸氧的频率更高。截至2月18日，1例患者死于急性大面积脑梗死，34例患者出院。结论老年合并多种心血管疾病的患者更易发生重症、危重型新冠肺炎，多合并多器官或系统异常，临床医生应根据临床症状、体征及实验室检查结果，及时判断并调整治疗方案

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中国药理学通报 Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

0.80

自引率

0.00%

发文量

11201

期刊介绍： Chinese Pharmacological Bulletin (CPB) is an academic monthly magazine sponsored by the Chinese Association for Science and Technology, the Chinese Pharmacological Society, and Anhui Medical University. Publicly issued domestically and internationally, CN:34:1086/R,ISSN:1001-1978。 The inclusion status of Chinese Pharmaceutical Bulletin (CPB): 1. This journal has been identified as a core medical journal by the China Science Citation Database (CSCD) of the Document Information Center of the Chinese Academy of Sciences (since 1993, there are 909 journals in the core library); 2. Selected as a pharmaceutical core journal by the editor in chief of Peking University Library's "Overview of Chinese Core Journals" (Peking University Core), 1st to 8th editions (1243 scientific and technological journals, including 232 medical and health journals); 3. Designated by the Institute of Science and Technology Information of the Ministry of Science and Technology of China as a source journal for Chinese scientific and technological paper statistics (China Science and Technology Core Journal); 4. Other: Domestic: Chinese Academic Journal Abstracts, Chinese Basic Medical Abstracts, Chinese Pharmaceutical Abstracts, Chinese Biological Abstracts, Chinese Academic Journals (CD version), Wanfang Database, VIP Database, etc; International: Chemical Abstract (USA), Corrective Bulletin on Science and Technology, CBST (Japan), Biological Abstract (USA), Biochemical Abstract (USA), EMBASE/Excerpta Medica (Netherlands), Index Copernicus (Poland), Kunst and Wissen (Germany), WPRIM (World Health Organization Western Pacific Regional Medical Index), Scopus (Netherlands, 2019 CiteScore 0.9), A&I (Netherlands), Centre for Agriculture and Biosciences international (CAB international, UK), Biosis Previews (USA), etc.